Published on March 25, 2026
Five years after the release of its previous Antimicrobial Resistance (AMR) Benchmark, the Access to Medicine Foundation has unveiled its 2026 report, highlighting a blend of advancements and urgent areas needing attention in the fight against superbugs. The report underscores that while pharmaceutical companies have made some strides, the pace of progress remains insufficient to combat the escalating threat posed -resistant pathogens.
The AMR Benchmark evaluates the efforts of pharmaceutical companies to address antimicrobial resistance, particularly focusing on their commitment to research and development (R&D), as well as their strategies for ensuring equitable access to essential medications. The 2026 report reveals that several leading companies have initiated promising initiatives aimed at bolstering the pipeline of novel antibiotics and enhancing access to existing treatments in low- and middle-income countries.
However, the report warns that the overall response is still lacking urgency. It emphasizes that significant gaps in access persist, especially in marginalized communities that are disproportionately affected . The Access to Medicine Foundation calls for a multifaceted approach that not only accelerates the development of new drugs but also reinforces healthcare systems to ensure that they can effectively deliver these treatments where they are needed most.
The benchmark findings indicate that while some biopharmaceutical companies have ramped up their investments in AMR research, many remain hesitant to prioritize antibiotic development due to limited economic incentives. The foundation advocates for innovative funding mechanisms and stronger public-private partnerships that can drive more sustainable investment in this crucial area.
Moreover, the report highlights the importance of policies that support the responsible use of antibiotics, which is essential to mitigate resistance. The Access to Medicine Foundation stresses the need for improved stewardship programs that ensure antibiotics are used appropriately across all sectors, including human health, animal agriculture, and environmental ecosystems.
In addition to policy reforms, the benchmark urges companies to enhance transparency regarding their AMR-related activities and commitments. and best practices, pharmaceutical companies can foster collaborative efforts that leverage collective resources and expertise to combat this global health crisis effectively.
The AMR Benchmark serves as a stark reminder that while progress is being made, the continued rise of antibiotic-resistant infections demands immediate and concerted action from all stakeholders. The Access to Medicine Foundation’s 2026 report is a clarion call for pharmaceutical companies, governments, and international organizations to prioritize the fight against superbugs to safeguard public health for future generations.